| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Revenue | $822.7M | -0.8% |
| Cost of Revenue | $178.7M | -4.6% |
| Gross Profit | $643.9M | +0.3% |
| R&D Expense | $152.9M | -5.2% |
| SG&A Expense | $96.7M | +0.9% |
| Operating Income | -$367.6M | -145.4% |
| Pre-tax Income | -$365.8M | -153.1% |
| Income Tax | $1.1M | -65.0% |
| Net Income | -$366.9M |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $457.4M | +17.4% |
| Accounts Receivable | $163.7M | -14.8% |
| Inventory | $12.9M | -8.5% |
| Current Assets | $713.2M | +6.1% |
| Total Assets | $2.19B | -15.7% |
| Current Liabilities | $407.9M | +3.3% |
| Long-term Debt | $0 | -100.0% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $217.7M | +270.1% |
| Capital Expenditures | $5.4M | -14.7% |
| Investing Cash Flow | -$7.0M | -152.4% |
| Financing Cash Flow | -$142.0M | -104.8% |
| Free Cash Flow | $212.3M | +304.5% |
| -148.4% |
| EPS (Basic) | -$5.12 | -147.3% |
| EPS (Diluted) | -$5.12 | -147.3% |
| Total Liabilities |
| $626.2M |
| -11.0% |
| Stockholders' Equity | $1.56B | -17.5% |